Enzymersatztherapien für lysosomale Speichererkrankungen

ZUSAMMENFASSUNG

Lysosomale Speichererkrankungen (LSDs) stellen eine Gruppe von > 70 Erkrankungen dar, die alle durch einen angeborenen Defekt der lysosomalen Funktion bedingt sind. Der klinische Verlauf ist durch Progredienz und Multiorganerkrankung mit u. a. Organomegalie, Skelettbeteiligung und z. T. Neurodegeneration charakterisiert.

Wichtigste Therapieoption der LSDs ist die Enzymersatztherapie (EET). Aktuell sind in Europa 17 Medikamente zur EET für 12 LSDs zugelassen. Langzeitdaten zeigen, dass die EET zu einer signifikanten Verbesserung einer Vielzahl von Krankheitsmanifestationen, der Lebensqualität sowie des Überlebens führt. Nebenwirkungen der EET sind v. a. immunologische Reaktionen, die zu allergischen Reaktionen oder zur Inaktivierung des infundierten Enzyms führen können. Nicht alle Organsysteme können durch die EET erreicht werden; hierzu zählt auch das zentrale Nervensystem, da die infundierten Enzyme nicht die Bluthirnschranke überwinden können.

Neue Präparate mit veränderter chemischer Struktur, die die erwähnten Limitationen der EET umgehen sollen, sind seit kurzem zugelassen oder noch in (prä)klinischer Entwicklung. Von ihnen ist eine weitere Verbesserung des Auskommens der Patient*innen mit LSDs zu erwarten.

ABSTRACT

Lysosomal storage disorders (LSDs) are a group of more than 70 different diseases, which are all caused by an inborn error of the lysosomal function. Clinical hallmarks are a progressive course of the disease and a multi-organ involvement with partly organomegaly, skeletal involvement and neurodegeneration in some of the patients.

Most important therapeutic option for LSDs is the enzyme replacement therapy (ERT). At the moment, 17 different drugs for ERT are approved in Europe for 12 different LSDs. Long-term data reveal a significant improvement of a multitude of organ manifestations, the outcome, and survival in patients with LSDs on ERT. Side effects of ERT include immunologic reactions, resulting in allergic reactions or inactivation of the infused enzyme. In addition, ERT does not reach all affected organ systems, especially it does not cross the blood brain barrier and thus, does not treat affections of the central nervous system.

New drugs with modified chemical structure are recently approved or in (pre)clinical testing. They address these problems and may result in a significant improvement of the outcome of patients with LSDs.

Schlüsselwörter

Lysosomale Speichererkrankungen - Enzymersatztherapie - Mannose-6-Phosphat-Rezeptor

Keywords

Lysosomal storage disorders - enzyme replacement therapy - mannose-6-phosphate receptor

Publication History

Article published online:
02 December 2024

• Literatur

• 1 Banugaria SG, Prater SN, Patel TT. et al Algorithm for the early diagnosis and treatment of patients with cross reactive immunologic material-negative classic infantile pompe disease: a step towards improving the efficacy of ERT. PLoS One 2013; 8: e67052
• 2 Biegstraaten M, Arngrímsson R, Barbey F. et al Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 2015; 10: 36
• 3 Burton BK, Jego V, Mikl J. et al Survival in idursulfase-treated and untreated patients with mucopolysaccharidosis type II: data from the Hunter Outcome Survey (HOS). J Inherit Metab Dis 2017; 40: 867-874
• 4 Chen HH, Sawamoto K, Mason RW. et al Enzyme replacement therapy for mucopolysaccharidoses; past, present, and future. J Hum Genet 2019; 64: 1153-1171
• 5 Chen M, Zhang L, Quan S. Enzyme replacement therapy for infantile-onset Pompe disease. Cochrane Database Syst Rev 2017; 11: CD011539
• 6 Dalmia S, Sharma R, Ramaswami U. et al Enzyme replacement therapy for late-onset Pompe disease. Cochrane Database Syst Rev 2023; 12: CD012993
• 7 Del Grosso A, Parlanti G, Mezzena R. et al Current treatment options and novel nanotechnology-driven enzyme replacement strategies for lysosomal storage disorders. Adv Drug Deliv Rev 2022; 188: 114464
• 8 Ditters IAM, Huidekoper HH, Kruijshaar ME. et al European Pompe Consortium project group on classic infantile Pompe disease. Effect of alglucosidase alfa dosage on survival and walking ability in patients with classic infantile Pompe disease: a multicentre observational cohort study from the European Pompe Consortium. Lancet Child Adolesc Health 2022; 6: 28-37
• 9 El Dib R, Gomaa H, Ortiz A. et al Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS One 2017; 12: e0173358
• 10 Harmatz P, Cattaneo F, Ardigò D. et al Enzyme replacement therapy with velmanase alfa (human recombinant alpha-mannosidase): Novel global treatment response model and outcomes in patients with alpha-mannosidosis. Mol Genet Metab 2018; 124: 152-160
• 11 Kaplan P, Baris H, De Meirleir L. et al Revised recommendations for the management of Gaucher disease in children. Eur J Pediatr 2013; 172: 447-58
• 12 Keam SJ. Olipudase Alfa: First Approval. Drugs 2022; 82: 941-947
• 13 Li C, Desai AK, Gupta P. et al Transforming the clinical outcome in CRIM-negative infantile Pompe disease identified via newborn screening: the benefits of early treatment with enzyme replacement therapy and immune tolerance induction. Genet Med 2021; 23: 845-855
• 14 Leonart LP, Fachi MM, Böger B. et al A Systematic Review and Meta-analyses of Longitudinal Studies on Drug Treatments for Gaucher Disease. Ann Pharmacother 2023; 57: 267-282
• 15 Leslie N, Bailey L. Pompe Disease. In: Adam MP, et al. eds. GeneReviews Seattle (WA): University of Washington; Seattle; 1993–2024
• 16 Malm D. Nilssen Ø. Alpha-mannosidosis. Orphanet J Rare Dis 2008; 3: 21
• 17 McGovern MM, Avetisyan R, Sanson BJ. et al Disease manifestations and burden of illness in patients with acid sphingomyelinase deficiency (ASMD). Orphanet J Rare Dis 2017; 12: 41
• 18 Mehta A, Hughes DA. Fabry Disease. In: Adam MP, et al. eds. GeneReviews. Seattle (WA): University of Washington; Seattle; 1993–2024
• 19 Muenzer J. Overview of the mucopolysaccharidoses. Rheumatology 2011; 50 Suppl 5 v4-12
• 20 Platt FM, d’Azzo A, Davidson BL. et al Lysosomal storage diseases. Nat Rev Dis Primers 2018; 4: 27
• 21 Sahin O, Thompson HP, Goodman GW. et al Mucopolysaccharidoses and the blood-brain barrier. Fluids Barriers CNS 2022; 19: 76
• 22 Stirnemann J, Belmatoug N, Camou F. et al A Review of Gaucher Disease Pathophysiology, Clinical Presentations, and Treatments. Int J Mol Sci 2017; 18: 441
• 23 van Kooten HA, Harlaar L, van der Beek NAME. et al Erasmus MC Pompe expert committee. Discontinuation of enzyme replacement therapy in adults with Pompe disease: Evaluating the European POmpe Consortium stop criteria. Neuromuscul Disord 2020; 30: 59-66
• 24 Wikman-Jorgensen PE, López Amorós A, Peris García J. et al Enzyme replacement therapy for the treatment of Hunter disease: A systematic review with narrative synthesis and meta-analysis. Mol Genet Metab 2020; 131: 206-210
• 25 https://www.ema.europa.eu/en/documents/product-information/nexviadyme-epar-product-information_en.pdf Stand: 24.9.2024